Mirum Pharmaceuticals (MIRM) EBIAT (2020 - 2025)
Historic EBIAT for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $2.9 million.
- Mirum Pharmaceuticals' EBIAT rose 12040.74% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.4 million, marking a year-over-year increase of 5849.86%. This contributed to the annual value of -$87.9 million for FY2024, which is 4618.49% up from last year.
- According to the latest figures from Q3 2025, Mirum Pharmaceuticals' EBIAT is $2.9 million, which was up 12040.74% from -$5.9 million recorded in Q2 2025.
- Mirum Pharmaceuticals' 5-year EBIAT high stood at $57.5 million for Q4 2021, and its period low was -$74.0 million during Q2 2023.
- Its 5-year average for EBIAT is -$25.7 million, with a median of -$26.9 million in 2022.
- Its EBIAT has fluctuated over the past 5 years, first skyrocketed by 25468.11% in 2021, then tumbled by 17500.93% in 2023.
- Mirum Pharmaceuticals' EBIAT (Quarter) stood at $57.5 million in 2021, then tumbled by 163.31% to -$36.4 million in 2022, then increased by 2.12% to -$35.7 million in 2023, then skyrocketed by 33.28% to -$23.8 million in 2024, then skyrocketed by 112.21% to $2.9 million in 2025.
- Its EBIAT stands at $2.9 million for Q3 2025, versus -$5.9 million for Q2 2025 and -$14.7 million for Q1 2025.